# Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC

Source: https://onco.cc/trials/nct07244874/  
OnCo record `nct07244874` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of sacituzumab tirumotecan and toripalimab in triple-negative breast cancer, run by Tianjin Medical University Cancer Institute and Hospital, not yet recruiting.

## Summary

Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC is a phase 2, interventional study registered as NCT07244874 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 41 participants, started 2025-12-01 and due to reach its primary completion in 2028-01-30. Interventions recorded: Sacituzumab tirumotecan; Toripalimab. Conditions listed: TNBC - Triple-Negative Breast Cancer; PD-L1 Positive. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07244874
- Phase: 2
- Setting: A Single Arm, Phase II Study of Sacituzumab Tirumotecan（Sac-TMT） Combined With Toripalimab for First-line Treatment of PD-L1 Positive Unresectable Locally Advanced/Metastatic Triple Negative Breast Cancer (a/mTNBC)
- Sponsor: Tianjin Medical University Cancer Institute and Hospital
- Enrolled: 41

## Sources

- ClinicalTrials.gov NCT07244874: https://clinicaltrials.gov/study/NCT07244874

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Sacituzumab tirumotecan](https://onco.cc/drugs/sacituzumab-tirumotecan/), [Toripalimab](https://onco.cc/drugs/toripalimab/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07244874.json